- Home
- BCTX vs SMTK Comparison
BCTX vs SMTK Comparison
Compare BCTX & SMTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- SMTK
- Stock Information
- Founded
- BCTX 2014
- SMTK 2009
- Country
- BCTX Canada
- SMTK United Kingdom
- Employees
- BCTX N/A
- SMTK N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- SMTK
- Sector
- BCTX Health Care
- SMTK
- Exchange
- BCTX Nasdaq
- SMTK NYSE
- Market Cap
- BCTX 16.1M
- SMTK 13.3M
- IPO Year
- BCTX N/A
- SMTK N/A
- Fundamental
- Price
- BCTX $3.41
- SMTK $1.37
- Analyst Decision
- BCTX Strong Buy
- SMTK
- Analyst Count
- BCTX 1
- SMTK 0
- Target Price
- BCTX $32.00
- SMTK N/A
- AVG Volume (30 Days)
- BCTX 791.2K
- SMTK 88.8K
- Earning Date
- BCTX 06-13-2025
- SMTK 05-13-2025
- Dividend Yield
- BCTX N/A
- SMTK N/A
- EPS Growth
- BCTX N/A
- SMTK N/A
- EPS
- BCTX N/A
- SMTK N/A
- Revenue
- BCTX N/A
- SMTK $105,000.00
- Revenue This Year
- BCTX N/A
- SMTK N/A
- Revenue Next Year
- BCTX N/A
- SMTK N/A
- P/E Ratio
- BCTX N/A
- SMTK N/A
- Revenue Growth
- BCTX N/A
- SMTK 854.54
- 52 Week Low
- BCTX $2.81
- SMTK $1.00
- 52 Week High
- BCTX $29.40
- SMTK $8.25
- Technical
- Relative Strength Index (RSI)
- BCTX 47.56
- SMTK N/A
- Support Level
- BCTX $2.81
- SMTK N/A
- Resistance Level
- BCTX $3.69
- SMTK N/A
- Average True Range (ATR)
- BCTX 0.28
- SMTK 0.00
- MACD
- BCTX 0.06
- SMTK 0.00
- Stochastic Oscillator
- BCTX 65.93
- SMTK 0.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.